UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15776) 15776
Book Chapter (396) 396
Newspaper Article (170) 170
Newsletter (91) 91
Magazine Article (45) 45
Book / eBook (17) 17
Conference Proceeding (8) 8
Streaming Video (5) 5
Dissertation (4) 4
Web Resource (4) 4
Government Document (3) 3
Book Review (2) 2
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14082) 14082
science & technology (11694) 11694
life sciences & biomedicine (11264) 11264
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6655) 6655
hematology (6157) 6157
male (5899) 5899
oncology (5766) 5766
female (5471) 5471
adult (4915) 4915
middle aged (4591) 4591
chronic myeloid leukemia (4289) 4289
leukemia (3991) 3991
imatinib mesylate (3799) 3799
leukemia, myelogenous, chronic, bcr-abl positive - genetics (3618) 3618
leukemia, myelogenous, chronic, bcr-abl positive - therapy (3282) 3282
antineoplastic agents - therapeutic use (3081) 3081
leukemia, myelogenous, chronic, bcr-abl positive - pathology (3054) 3054
benzamides (3050) 3050
aged (2786) 2786
pyrimidines - therapeutic use (2756) 2756
piperazines - therapeutic use (2363) 2363
fusion proteins, bcr-abl - genetics (2051) 2051
treatment outcome (2046) 2046
hemic and lymphatic diseases (1924) 1924
adolescent (1901) 1901
cancer (1802) 1802
protein kinase inhibitors - therapeutic use (1786) 1786
animals (1775) 1775
imatinib (1665) 1665
research (1466) 1466
care and treatment (1403) 1403
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (1343) 1343
abridged index medicus (1271) 1271
mutation (1242) 1242
prognosis (1235) 1235
antineoplastic agents - pharmacology (1208) 1208
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (1188) 1188
bone marrow transplantation (1115) 1115
stem cells (1108) 1108
philadelphia chromosome (1106) 1106
transplantation (1105) 1105
apoptosis (1099) 1099
kinases (1080) 1080
pyrimidines - pharmacology (1072) 1072
genetic aspects (1069) 1069
protein-tyrosine kinases - antagonists & inhibitors (1066) 1066
child (1060) 1060
cml (1055) 1055
tyrosine (1041) 1041
mice (1039) 1039
transplantation, homologous (990) 990
dasatinib (984) 984
drug resistance, neoplasm (974) 974
leukemia, myelogenous, chronic, bcr-abl positive - mortality (961) 961
analysis (939) 939
antineoplastic agents - adverse effects (932) 932
cell line, tumor (931) 931
remission induction (922) 922
piperazines - pharmacology (917) 917
young adult (907) 907
aged, 80 and over (904) 904
apoptosis - drug effects (893) 893
antineoplastic combined chemotherapy protocols - therapeutic use (885) 885
fusion proteins, bcr-abl - metabolism (880) 880
pyrimidines - adverse effects (880) 880
health aspects (860) 860
k562 cells (859) 859
bone marrow (848) 848
cell biology (846) 846
drug therapy (844) 844
leukemia, myelogenous, chronic, bcr-abl positive - complications (844) 844
myeloid leukemia (841) 841
chronic myelogenous leukemia (833) 833
hematology, oncology and palliative medicine (826) 826
pyrimidines - administration & dosage (825) 825
medicine & public health (823) 823
immunology (821) 821
protein kinase inhibitors - pharmacology (789) 789
bcr-abl (781) 781
proteins (777) 777
hematopoietic stem cell transplantation (767) 767
interferon-alpha - therapeutic use (762) 762
antineoplastic agents (733) 733
time factors (733) 733
follow-up studies (730) 730
risk factors (725) 725
recurrence (724) 724
fusion proteins, bcr-abl - antagonists & inhibitors (718) 718
gene expression (718) 718
retrospective studies (702) 702
pharmacology & pharmacy (701) 701
antineoplastic agents - administration & dosage (690) 690
chemotherapy (681) 681
piperazines - administration & dosage (668) 668
antimitotic agents (637) 637
biochemistry & molecular biology (629) 629
leukemia, myelogenous, chronic, bcr-abl positive - immunology (629) 629
piperazines - adverse effects (629) 629
patients (625) 625
drug resistance (618) 618
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15616) 15616
Japanese (384) 384
Chinese (225) 225
German (137) 137
French (119) 119
Spanish (109) 109
Russian (98) 98
Polish (56) 56
Italian (34) 34
Portuguese (34) 34
Hungarian (32) 32
Czech (25) 25
Danish (16) 16
Dutch (13) 13
Korean (6) 6
Norwegian (6) 6
Serbian (6) 6
Romanian (5) 5
Slovak (5) 5
Swedish (5) 5
Ukrainian (5) 5
Croatian (4) 4
Finnish (4) 4
Hebrew (4) 4
Turkish (2) 2
Nauru (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 02/2014, Volume 32, Issue 5, pp. 415 - 423
... MR4.5 which was defined as 4.5 log reduction of BCR-ABL on the international scale (IS) and determined by reverse transcriptase polymerase chain reaction in two consecutive analyses... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
Blood, ISSN 1528-0020, 12/2007, Volume 110, Issue 12, pp. 4055 - 4063
Journal Article
Cancer, ISSN 0008-543X, 04/2005, Volume 103, Issue 8, pp. 1659 - 1669
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 09/2007, Volume 117, Issue 9, pp. 2408 - 2421
Journal Article
Cancer cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 428 - 442
Journal Article